Review




Structured Review

Abnova mouse anti-rac2
Mouse Anti Rac2, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-rac2/product/Abnova
Average 90 stars, based on 1 article reviews
mouse anti-rac2 - by Bioz Stars, 2026-03
90/100 stars

Images



Similar Products

86
Danaher Inc rac2 abcam ab191527 alexa fluor 647 anti mouse cd107a
Rac2 Abcam Ab191527 Alexa Fluor 647 Anti Mouse Cd107a, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rac2 abcam ab191527 alexa fluor 647 anti mouse cd107a/product/Danaher Inc
Average 86 stars, based on 1 article reviews
rac2 abcam ab191527 alexa fluor 647 anti mouse cd107a - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier

90
Millipore mouse anti-rac2 antibodies
Mouse Anti Rac2 Antibodies, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-rac2 antibodies/product/Millipore
Average 90 stars, based on 1 article reviews
mouse anti-rac2 antibodies - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Proteintech anti rac2 mouse monoclonal antibody
Chemokine-coupled β 2 integrin engagement drives <t>Rac2</t> activation (GTP-loading), Rac2-dependent HuR translocation, and consequent VEGF mRNA stabilization. (A) Rac2 and Myh9 immunoblots from lysates of WT BMDMs adhered to immobilized ICAM-1 or Fcγ fragment control for 5 min at 37°C in the presence or absence of 50 ng/ml CCL2, after which GTP-Rac2 was affinity precipitated by PBD pulldown ( n = 4). (B) Rac2, Myh9, Actin, and CCR2 immunoblots from lysates of Rac2 +/+ , Rac2 +/− , and Rac2 −/− BMDMs ( n = 3). (C) Relative CCR2 surface expression on thioglycollate-elicited peritoneal macrophages (CD11b hi F4/80 hi ) from Rac2 +/+ (red) and Rac2 −/− (blue) mice (isotype control; black, n = 4). (D) Confocal micrographs of Rac2 +/+ and Rac2 −/− BMDMs, CCL2-stimulated and ICAM-bound for 30 min, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin d at time 0, and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). Thioglycollate-elicited peritoneal macrophage data are from two independent experiments, each with two mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.
Anti Rac2 Mouse Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti rac2 mouse monoclonal antibody/product/Proteintech
Average 94 stars, based on 1 article reviews
anti rac2 mouse monoclonal antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
Abnova mouse anti-rac2
Chemokine-coupled β 2 integrin engagement drives <t>Rac2</t> activation (GTP-loading), Rac2-dependent HuR translocation, and consequent VEGF mRNA stabilization. (A) Rac2 and Myh9 immunoblots from lysates of WT BMDMs adhered to immobilized ICAM-1 or Fcγ fragment control for 5 min at 37°C in the presence or absence of 50 ng/ml CCL2, after which GTP-Rac2 was affinity precipitated by PBD pulldown ( n = 4). (B) Rac2, Myh9, Actin, and CCR2 immunoblots from lysates of Rac2 +/+ , Rac2 +/− , and Rac2 −/− BMDMs ( n = 3). (C) Relative CCR2 surface expression on thioglycollate-elicited peritoneal macrophages (CD11b hi F4/80 hi ) from Rac2 +/+ (red) and Rac2 −/− (blue) mice (isotype control; black, n = 4). (D) Confocal micrographs of Rac2 +/+ and Rac2 −/− BMDMs, CCL2-stimulated and ICAM-bound for 30 min, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin d at time 0, and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). Thioglycollate-elicited peritoneal macrophage data are from two independent experiments, each with two mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.
Mouse Anti Rac2, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-rac2/product/Abnova
Average 90 stars, based on 1 article reviews
mouse anti-rac2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Proteintech mouse anti rac2
Chemokine-coupled β 2 integrin engagement drives <t>Rac2</t> activation (GTP-loading), Rac2-dependent HuR translocation, and consequent VEGF mRNA stabilization. (A) Rac2 and Myh9 immunoblots from lysates of WT BMDMs adhered to immobilized ICAM-1 or Fcγ fragment control for 5 min at 37°C in the presence or absence of 50 ng/ml CCL2, after which GTP-Rac2 was affinity precipitated by PBD pulldown ( n = 4). (B) Rac2, Myh9, Actin, and CCR2 immunoblots from lysates of Rac2 +/+ , Rac2 +/− , and Rac2 −/− BMDMs ( n = 3). (C) Relative CCR2 surface expression on thioglycollate-elicited peritoneal macrophages (CD11b hi F4/80 hi ) from Rac2 +/+ (red) and Rac2 −/− (blue) mice (isotype control; black, n = 4). (D) Confocal micrographs of Rac2 +/+ and Rac2 −/− BMDMs, CCL2-stimulated and ICAM-bound for 30 min, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin d at time 0, and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). Thioglycollate-elicited peritoneal macrophage data are from two independent experiments, each with two mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.
Mouse Anti Rac2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti rac2/product/Proteintech
Average 94 stars, based on 1 article reviews
mouse anti rac2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology rabbit polyclonal anti rac2 antibody
Chemokine-coupled β 2 integrin engagement drives <t>Rac2</t> activation (GTP-loading), Rac2-dependent HuR translocation, and consequent VEGF mRNA stabilization. (A) Rac2 and Myh9 immunoblots from lysates of WT BMDMs adhered to immobilized ICAM-1 or Fcγ fragment control for 5 min at 37°C in the presence or absence of 50 ng/ml CCL2, after which GTP-Rac2 was affinity precipitated by PBD pulldown ( n = 4). (B) Rac2, Myh9, Actin, and CCR2 immunoblots from lysates of Rac2 +/+ , Rac2 +/− , and Rac2 −/− BMDMs ( n = 3). (C) Relative CCR2 surface expression on thioglycollate-elicited peritoneal macrophages (CD11b hi F4/80 hi ) from Rac2 +/+ (red) and Rac2 −/− (blue) mice (isotype control; black, n = 4). (D) Confocal micrographs of Rac2 +/+ and Rac2 −/− BMDMs, CCL2-stimulated and ICAM-bound for 30 min, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin d at time 0, and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). Thioglycollate-elicited peritoneal macrophage data are from two independent experiments, each with two mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.
Rabbit Polyclonal Anti Rac2 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal anti rac2 antibody/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
rabbit polyclonal anti rac2 antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


Chemokine-coupled β 2 integrin engagement drives Rac2 activation (GTP-loading), Rac2-dependent HuR translocation, and consequent VEGF mRNA stabilization. (A) Rac2 and Myh9 immunoblots from lysates of WT BMDMs adhered to immobilized ICAM-1 or Fcγ fragment control for 5 min at 37°C in the presence or absence of 50 ng/ml CCL2, after which GTP-Rac2 was affinity precipitated by PBD pulldown ( n = 4). (B) Rac2, Myh9, Actin, and CCR2 immunoblots from lysates of Rac2 +/+ , Rac2 +/− , and Rac2 −/− BMDMs ( n = 3). (C) Relative CCR2 surface expression on thioglycollate-elicited peritoneal macrophages (CD11b hi F4/80 hi ) from Rac2 +/+ (red) and Rac2 −/− (blue) mice (isotype control; black, n = 4). (D) Confocal micrographs of Rac2 +/+ and Rac2 −/− BMDMs, CCL2-stimulated and ICAM-bound for 30 min, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin d at time 0, and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). Thioglycollate-elicited peritoneal macrophage data are from two independent experiments, each with two mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.

Journal: The Journal of Experimental Medicine

Article Title: Chemokine-coupled β 2 integrin–induced macrophage Rac2–Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis

doi: 10.1084/jem.20132130

Figure Lengend Snippet: Chemokine-coupled β 2 integrin engagement drives Rac2 activation (GTP-loading), Rac2-dependent HuR translocation, and consequent VEGF mRNA stabilization. (A) Rac2 and Myh9 immunoblots from lysates of WT BMDMs adhered to immobilized ICAM-1 or Fcγ fragment control for 5 min at 37°C in the presence or absence of 50 ng/ml CCL2, after which GTP-Rac2 was affinity precipitated by PBD pulldown ( n = 4). (B) Rac2, Myh9, Actin, and CCR2 immunoblots from lysates of Rac2 +/+ , Rac2 +/− , and Rac2 −/− BMDMs ( n = 3). (C) Relative CCR2 surface expression on thioglycollate-elicited peritoneal macrophages (CD11b hi F4/80 hi ) from Rac2 +/+ (red) and Rac2 −/− (blue) mice (isotype control; black, n = 4). (D) Confocal micrographs of Rac2 +/+ and Rac2 −/− BMDMs, CCL2-stimulated and ICAM-bound for 30 min, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin d at time 0, and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). Thioglycollate-elicited peritoneal macrophage data are from two independent experiments, each with two mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.

Article Snippet: Anti-Rac2 mouse monoclonal antibody was purchased from Proteintech.

Techniques: Activation Assay, Translocation Assay, Western Blot, Control, Expressing, Immunostaining, Quantitative RT-PCR

Chemokine-coupled integrin-driven activation of Rac2 leads to a unique Rac2-Myh9 complex that correlates with HuR translocation, and in vivo neovascular responses depend on efficient integrin activation of Rac2. (A) THP-1 cells in the presence or absence of CCL2 (50 ng/ml × 10 min) were lysed and GTPγS (or vehicle control)-loaded, followed by PBD affinity pulldown and Coomassie staining (top) or immunoblotting for the indicated Rho family GTPases (bottom; n = 3). (B) Chemokine stimulation and GTP loading as in A, in Rac2 +/+ or Rac2 −/− BMDMs, followed by PBD affinity pulldown and Coomassie staining for the 226 kD protein noted above ( n = 3). (C) Immunoblots from lysates of Rac2 +/+ and Rac2 −/− BMDMs, which were CCL2-treated for 10 min, GTPγS (100 µM)-loaded for 10 min, and affinity precipitated with PBD beads to determine the association of Myh9 with the indicated Rac proteins ( n = 4). (D) Confocal micrographs of human peripheral blood monocytes adhered to ICAM-1 or Fcγ fragment control in the presence or absence of 50 ng/ml CCL2 for 10 min, followed by PLA reaction for Rac2–Myh9 interaction (red signal) and DAPI (cyan) staining ( n = 3). Bar, 15 µm. (E) PLA-HuR translocation correlation graph. THP-1 HuR-YFP stable transfectants were ICAM-1– or poly- l -lysine control-bound in the presence or absence of CCL2, after which PLA and HuR translocation analysis were performed ( r = 0.9, P < 0.0001, n = 3). (F) Rac2 and Myh9 immunoblots from lysates of Rac2 +/+ or Rac2 +/− BMDMs adhered to immobilized ICAM-1 in the presence of 50 ng/ml CCL2, after which Rac2 was affinity precipitated by PBD pulldown ( n = 3). (G and H) Laser Doppler scan images (G) of flow in the ischemic (I) and contralateral control (C) hind limb of Rac2 +/+ and Rac2 +/− mice at the indicated time points before and after femoral artery ligation with quantitative blood flow analysis (H; **, P < 0.0025; n = 10). (I) Quantification of CD11b hi F4/80 hi macrophages isolated from collagenase-treated ischemic muscle tissue at day 3 after femoral artery ligation (**, P < 0.0001; n = 6). Animal data are from 2 independent experiments, each with 3 mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.

Journal: The Journal of Experimental Medicine

Article Title: Chemokine-coupled β 2 integrin–induced macrophage Rac2–Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis

doi: 10.1084/jem.20132130

Figure Lengend Snippet: Chemokine-coupled integrin-driven activation of Rac2 leads to a unique Rac2-Myh9 complex that correlates with HuR translocation, and in vivo neovascular responses depend on efficient integrin activation of Rac2. (A) THP-1 cells in the presence or absence of CCL2 (50 ng/ml × 10 min) were lysed and GTPγS (or vehicle control)-loaded, followed by PBD affinity pulldown and Coomassie staining (top) or immunoblotting for the indicated Rho family GTPases (bottom; n = 3). (B) Chemokine stimulation and GTP loading as in A, in Rac2 +/+ or Rac2 −/− BMDMs, followed by PBD affinity pulldown and Coomassie staining for the 226 kD protein noted above ( n = 3). (C) Immunoblots from lysates of Rac2 +/+ and Rac2 −/− BMDMs, which were CCL2-treated for 10 min, GTPγS (100 µM)-loaded for 10 min, and affinity precipitated with PBD beads to determine the association of Myh9 with the indicated Rac proteins ( n = 4). (D) Confocal micrographs of human peripheral blood monocytes adhered to ICAM-1 or Fcγ fragment control in the presence or absence of 50 ng/ml CCL2 for 10 min, followed by PLA reaction for Rac2–Myh9 interaction (red signal) and DAPI (cyan) staining ( n = 3). Bar, 15 µm. (E) PLA-HuR translocation correlation graph. THP-1 HuR-YFP stable transfectants were ICAM-1– or poly- l -lysine control-bound in the presence or absence of CCL2, after which PLA and HuR translocation analysis were performed ( r = 0.9, P < 0.0001, n = 3). (F) Rac2 and Myh9 immunoblots from lysates of Rac2 +/+ or Rac2 +/− BMDMs adhered to immobilized ICAM-1 in the presence of 50 ng/ml CCL2, after which Rac2 was affinity precipitated by PBD pulldown ( n = 3). (G and H) Laser Doppler scan images (G) of flow in the ischemic (I) and contralateral control (C) hind limb of Rac2 +/+ and Rac2 +/− mice at the indicated time points before and after femoral artery ligation with quantitative blood flow analysis (H; **, P < 0.0025; n = 10). (I) Quantification of CD11b hi F4/80 hi macrophages isolated from collagenase-treated ischemic muscle tissue at day 3 after femoral artery ligation (**, P < 0.0001; n = 6). Animal data are from 2 independent experiments, each with 3 mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.

Article Snippet: Anti-Rac2 mouse monoclonal antibody was purchased from Proteintech.

Techniques: Activation Assay, Translocation Assay, In Vivo, Control, Staining, Western Blot, Ligation, Isolation

Macrophage HuR translocation with consequent VEGF-A mRNA stabilization, flow recovery during hind limb ischemia, and tissue VEGF-A mRNA levels depend on myeloid Myh9. (A) Myh9, Actin, Rac2, and CCR2 immunoblots of lysates obtained from BMDMs isolated from LysM +/cre Myh9 +/+ ( Myh9 +/+ ), LysM +/cre Myh9 +/fl ( Myh9 +/− ), and LysM +/cre Myh9 fl/fl ( Myh9 −/− ) mice ( n = 3). (B) Flow cytometric CD11b and Ly6C phenotyping (top) of density gradient–enriched peripheral blood mononuclear cells obtained from myeloid cell–specific Myh9 +/− and Myh9 −/− mice along with quantification of absolute cell count per ml blood (lower panel, n = 4). (C) Flow cytometric CD11b and F4/80 phenotyping (top) of cells recovered from the peritoneal cavity 3 d after initiation of thioglycollate-induced peritonitis in myeloid cell–specific Myh9 +/− and Myh9 −/− mice along with quantification of absolute cell count per ml blood (bottom, n = 5). (D) Confocal micrographs of Myh9 +/− and Myh9 −/− BMDMs, CCL2-stimulated and ICAM-bound, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin (time 0), and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). (G and H) Laser Doppler scan images (G) of flow in the ischemic (I) and contralateral control (C) hind limb of Myh9 +/− and Myh9 −/− mice at the indicated time points before and after femoral artery ligation with quantitative blood flow analysis (H; **, P < 0.0006; n = 7). (I) Real-time PCR quantification of VEGF-A mRNA in thigh (adductor) muscle tissue obtained 3 d after femoral artery ligation (**, P = 0.003; n = 4). Animal data are from 3 independent experiments, each with 2–3 mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.

Journal: The Journal of Experimental Medicine

Article Title: Chemokine-coupled β 2 integrin–induced macrophage Rac2–Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis

doi: 10.1084/jem.20132130

Figure Lengend Snippet: Macrophage HuR translocation with consequent VEGF-A mRNA stabilization, flow recovery during hind limb ischemia, and tissue VEGF-A mRNA levels depend on myeloid Myh9. (A) Myh9, Actin, Rac2, and CCR2 immunoblots of lysates obtained from BMDMs isolated from LysM +/cre Myh9 +/+ ( Myh9 +/+ ), LysM +/cre Myh9 +/fl ( Myh9 +/− ), and LysM +/cre Myh9 fl/fl ( Myh9 −/− ) mice ( n = 3). (B) Flow cytometric CD11b and Ly6C phenotyping (top) of density gradient–enriched peripheral blood mononuclear cells obtained from myeloid cell–specific Myh9 +/− and Myh9 −/− mice along with quantification of absolute cell count per ml blood (lower panel, n = 4). (C) Flow cytometric CD11b and F4/80 phenotyping (top) of cells recovered from the peritoneal cavity 3 d after initiation of thioglycollate-induced peritonitis in myeloid cell–specific Myh9 +/− and Myh9 −/− mice along with quantification of absolute cell count per ml blood (bottom, n = 5). (D) Confocal micrographs of Myh9 +/− and Myh9 −/− BMDMs, CCL2-stimulated and ICAM-bound, followed by HuR immunostaining for translocation analysis. Bar, 10 µm. (E) Quantification of percentage of cells in D with HuR nuclear-to-cytosolic translocation (**, P < 0.002; n = 3). (F) VEGF-A mRNA decay assays, using the indicated BMDMs, adhered to immobilized ICAM-1 or Fcγ fragment control in the presence or absence of CCL2 for 30 min, after which transcription was arrested with 10 mg/ml actinomycin (time 0), and RNA collected at the noted time points for VEGF-A mRNA quantification by RT-qPCR (**, P = 0.0001; n = 5). (G and H) Laser Doppler scan images (G) of flow in the ischemic (I) and contralateral control (C) hind limb of Myh9 +/− and Myh9 −/− mice at the indicated time points before and after femoral artery ligation with quantitative blood flow analysis (H; **, P < 0.0006; n = 7). (I) Real-time PCR quantification of VEGF-A mRNA in thigh (adductor) muscle tissue obtained 3 d after femoral artery ligation (**, P = 0.003; n = 4). Animal data are from 3 independent experiments, each with 2–3 mice per treatment group. Remaining data are representative of at least 3 independent experiments. Quantitative data are displayed as mean ± SEM.

Article Snippet: Anti-Rac2 mouse monoclonal antibody was purchased from Proteintech.

Techniques: Translocation Assay, Western Blot, Isolation, Cell Counting, Immunostaining, Control, Quantitative RT-PCR, Ligation, Real-time Polymerase Chain Reaction